Tags

Type your tag names separated by a space and hit enter

Time-effect of montelukast on protection against exercise-induced bronchoconstriction.
Respir Med. 2011 Dec; 105(12):1790-7.RM

Abstract

INTRODUCTION

Montelukast has been proven to assure a protective effect against exercise-induced bronchoconstriction.

AIM

To verify exactly when montelukast begins protection in asthmatic children by evaluating different time intervals between dosing and challenge.

METHODS

In a double blind, placebo-controlled, three day doses, crossover study, patients were randomized to receive in sequence treatment with either a placebo or montelukast and assigned to one of seven groups that were tested 1, 2, 3, 4, 5, 6 and 8 h after drug administration, respectively. For each group, the exercise challenge was always performed at the same hour on the first and third days of treatment.

RESULTS

Sixty-nine asthmatic children took part in the study. On day 3, the mean FEV(1) % fall from baseline was 25.54 (95% CI = 21.63/29.46) and 14.89 (95% CI = 11.85/17.92) for the placebo and active drug (p < 0.05), respectively. On day 1, the mean fall of FEV(1) was 28.20 (95% CI = 24.46/31.94) and 19.01 (95% CI = 15.71/22.31) for the placebo and montelukast (p < 0.05), respectively. Clinical protection was achieved in 21 (30%) and 33 (48%) subjects by montelukast on the first and third days, respectively.

CONCLUSIONS

Montelukast assured protection against exercise-induced bronchoconstriction from the first through the eighth hour from the first day of treatment. However, individual susceptibility to protection was evident since some individuals were not protected at any time. We conclude that in clinical use individual responses to the drug should be carefully evaluated in the follow-up management.

Authors+Show Affiliations

Pediatric Department, University of Verona, Verona, Italy. diego.peroni@univr.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

21865022

Citation

Peroni, Diego G., et al. "Time-effect of Montelukast On Protection Against Exercise-induced Bronchoconstriction." Respiratory Medicine, vol. 105, no. 12, 2011, pp. 1790-7.
Peroni DG, Pescollderungg L, Sandri M, et al. Time-effect of montelukast on protection against exercise-induced bronchoconstriction. Respir Med. 2011;105(12):1790-7.
Peroni, D. G., Pescollderungg, L., Sandri, M., Chinellato, I., Boner, A. L., & Piacentini, G. L. (2011). Time-effect of montelukast on protection against exercise-induced bronchoconstriction. Respiratory Medicine, 105(12), 1790-7. https://doi.org/10.1016/j.rmed.2011.08.007
Peroni DG, et al. Time-effect of Montelukast On Protection Against Exercise-induced Bronchoconstriction. Respir Med. 2011;105(12):1790-7. PubMed PMID: 21865022.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Time-effect of montelukast on protection against exercise-induced bronchoconstriction. AU - Peroni,Diego G, AU - Pescollderungg,Lydia, AU - Sandri,Marco, AU - Chinellato,Iolanda, AU - Boner,Attilio L, AU - Piacentini,Giorgio L, Y1 - 2011/08/23/ PY - 2011/04/04/received PY - 2011/07/13/revised PY - 2011/08/08/accepted PY - 2011/8/26/entrez PY - 2011/8/26/pubmed PY - 2012/1/26/medline SP - 1790 EP - 7 JF - Respiratory medicine JO - Respir Med VL - 105 IS - 12 N2 - INTRODUCTION: Montelukast has been proven to assure a protective effect against exercise-induced bronchoconstriction. AIM: To verify exactly when montelukast begins protection in asthmatic children by evaluating different time intervals between dosing and challenge. METHODS: In a double blind, placebo-controlled, three day doses, crossover study, patients were randomized to receive in sequence treatment with either a placebo or montelukast and assigned to one of seven groups that were tested 1, 2, 3, 4, 5, 6 and 8 h after drug administration, respectively. For each group, the exercise challenge was always performed at the same hour on the first and third days of treatment. RESULTS: Sixty-nine asthmatic children took part in the study. On day 3, the mean FEV(1) % fall from baseline was 25.54 (95% CI = 21.63/29.46) and 14.89 (95% CI = 11.85/17.92) for the placebo and active drug (p < 0.05), respectively. On day 1, the mean fall of FEV(1) was 28.20 (95% CI = 24.46/31.94) and 19.01 (95% CI = 15.71/22.31) for the placebo and montelukast (p < 0.05), respectively. Clinical protection was achieved in 21 (30%) and 33 (48%) subjects by montelukast on the first and third days, respectively. CONCLUSIONS: Montelukast assured protection against exercise-induced bronchoconstriction from the first through the eighth hour from the first day of treatment. However, individual susceptibility to protection was evident since some individuals were not protected at any time. We conclude that in clinical use individual responses to the drug should be carefully evaluated in the follow-up management. SN - 1532-3064 UR - https://www.unboundmedicine.com/medline/citation/21865022/Time_effect_of_montelukast_on_protection_against_exercise_induced_bronchoconstriction_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0954-6111(11)00284-8 DB - PRIME DP - Unbound Medicine ER -